Ozempic: Semaglutide for Type 2 Diabetes and Cardiovascular Risk

Ozempic contains semaglutide, a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. It enhances glucose-dependent insulin secretion, suppresses glucagon, and delays gastric emptying. By acting on brain appetite centers, it also reduces hunger and caloric intake, which contributes to weight loss as a secondary benefit in patients with type 2 diabetes.

Ozempic is a brand-name prescription medication containing semaglutide, a GLP-1 receptor agonist. It was approved by the FDA in December 2017 for the treatment of type 2 diabetes mellitus and later received a cardiovascular risk reduction indication based on the SUSTAIN 6 trial. Ozempic is administered as a once-weekly subcutaneous injection using a pre-filled, multi-dose pen. While Ozempic is FDA-approved only for diabetes, it contains the same active ingredient as Wegovy (which is approved for weight management) and has been widely prescribed off-label for weight loss, contributing to significant supply challenges.

Ozempic and Wegovy both contain semaglutide and are manufactured by Novo Nordisk, but they are approved for different indications and come in different dose ranges. Ozempic is approved for type 2 diabetes with doses up to 2 mg, while Wegovy is approved for chronic weight management with doses up to 2.4 mg. The titration schedules differ accordingly. Insurance coverage also varies: most plans cover Ozempic for diabetes but may not cover Wegovy for weight management. Despite containing the same molecule, they are not interchangeable prescriptions, and pharmacies cannot substitute one for the other.

The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) clinical trial program consisted of over 10 trials evaluating Ozempic across a wide range of patient populations and comparator therapies. SUSTAIN 6 was the landmark cardiovascular outcomes trial demonstrating a 26% reduction in MACE (major adverse cardiovascular events) over 2 years. Across the SUSTAIN program, Ozempic consistently demonstrated superior HbA1c reduction compared to placebo and active comparators including sitagliptin, insulin glargine, dulaglutide, and liraglutide. Weight loss was a consistent secondary benefit, typically ranging from 3.5-6.5 kg depending on the study duration and dose.

Ozempic comes in pre-filled, multi-dose pens that deliver either 0.25 mg or 0.5 mg per injection (from one pen) or 1 mg or 2 mg per injection (from separate pen configurations). Before first use, the pen should be stored in the refrigerator. To administer, attach a new NovoFine or NovoTwist needle, prime the pen, dial the dose, and inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites to reduce the risk of lipodystrophy. The same day each week should be used for consistency, but the day can be changed if the last dose was at least 2 days prior. After first use, the pen can be stored at room temperature (up to 86 degrees F) or refrigerated for up to 56 days.

Ozempic has broader insurance coverage than Wegovy because it is approved for type 2 diabetes, which insurance plans are generally required to cover. Most commercial insurance plans and many Medicare Part D plans include Ozempic on their formularies, though it may be placed on a higher tier requiring prior authorization or step therapy (trying metformin first). The Novo Nordisk savings card can reduce commercial copays to as low as $25 per month for eligible patients. For patients without insurance or with high deductibles, the cash price is typically $900-$1,100 per month, though discount programs and pharmacy coupons can lower this.